Peytant presents at AABIP 2025
MINNEAPOLIS (Aug. 5, 2025) -- Peytant Solutions Inc., the medical technology company that has developed the first and only stent covered with decellularized human amniotic membrane (DCAM) to receive FDA DeNovo granted clearance, the AMStent® System, announced today that Dr. Roy Joseph Cho, MD, MHA associate professor of Interventional Pulmonology at University of Minnesota, will present new research at the 2025 American Association for Bronchology and Interventional Pulmonology (AABIP) Annual Meeting.
Dr. Cho will present a poster session titled “Evaluating the Novel Peytant® AMStent® in a Porcine Bronchus Model” on Aug. 18 at 1:45pm.
“The findings demonstrate favorable outcomes compared to synthetic-covered control stents, which may trigger the body's natural response to foreign materials,” said Dr. Cho. “I look forward to sharing more details from this important research.”
“We’re on a mission to fundamentally transform the treatment of luminal diseases using patented, foundational technology for covering stents with proprietary biomaterials,” said John Schorgl, cofounder, CEO, and board chair at Peytant Solutions.
The AMStent Tracheobronchial Covered Stent System is Peytant’s first commercial product. It is indicated to treat tracheobronchial strictures produced by malignant neoplasms (cancer) in adult patients. Amnion, the foundation of AMStent’s DCAM covering, contains naturally occurring structural proteins such as collagen, keratin, fibronectins, and laminins rather than synthetic forever chemicals such as expanded polytetraflouroethylene (ePTFE) and thermoplastic polyurethanes (TPUs) found in the coverings of other commercially available airway stents. Peytant has developed a proprietary decellularization process that converts amnion to DCAM. The AMStent is designed to reduce airway trauma, mitigate granulation tissue formation, minimize mucus buildup, and lower the risk of stent migration—all key challenges in the management of malignant airway obstruction with current stent technology.
Lung cancer remains the leading cause of cancer-related death in the United States, with approximately 226,650 new cases and an estimated 124,730 deaths projected in 2025. More people in the U.S. die from lung cancer than any other type of cancer; it accounts for roughly 20 percent of all cancer deaths.
Malignant airway obstructions occur in roughly 25 percent of lung cancer patients. These obstructions can severely compromise breathing and quality of life, making airway stenting a critical intervention. The AMStent offers a new and improved therapeutic approach to supporting these patients.
About Peytant Solutions, Inc.
Peytant is a medical technology manufacturer seeking to improve outcomes for patients with luminal blockages. Minneapolis-based Peytant is focused on commercializing the AMStent System, a platform technology comprising an amnion-based covered stent and catheter delivery system. Peytant's AMStent® System is the first step toward transforming the treatment of luminal diseases.